利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

34 条记录 (耗时 0.037 秒)

    Anti-OX40 antibodies and methods of treating cancer
    1.
    发明授权
    Anti-OX40 antibodies and methods of treating cancer 有权
    抗OX40抗体及其治疗方法

    公开(公告)号：US09163085B2

    公开(公告)日：2015-10-20

    申请号：US14240535

    申请日：2012-02-09

    申请人： Yong-Jun Liu ,  Kui Shin Voo ,  Laura Bover ,  Naoya Tsurushita ,  J. Yun Tso ,  Shankar Kumar

    发明人： Yong-Jun Liu ,  Kui Shin Voo ,  Laura Bover ,  Naoya Tsurushita ,  J. Yun Tso ,  Shankar Kumar

    IPC分类号： C07K16/28 ,  A61K39/00

    CPC分类号： C07K16/2878 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/74 ,  C07K2317/75

    摘要： Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided.

    摘要翻译： 公开了与人OX40特异性结合的人抗体，优选重组人抗体，人源化和嵌合。 优选的抗体对OX40受体具有高亲和力，并在体外和体内激活受体。 抗体可以是全长抗体或其抗原结合部分。 抗体或抗体部分可用于调节受体活性，例如在患有OX40活性有害的病症的人类受试者中。 提供用于表达重组人抗体的核酸，载体和宿主细胞，并提供合成重组人抗体的方法。

    ANTI-OX40 ANTIBODIES AND METHODS OF USING THE SAME
    2.
    发明申请
    ANTI-OX40 ANTIBODIES AND METHODS OF USING THE SAME 有权
    抗OX40抗体及其使用方法

    公开(公告)号：US20140308276A1

    公开(公告)日：2014-10-16

    申请号：US14240535

    申请日：2012-02-09

    申请人： Yong-Jun Liu ,  Kui Shin Voo ,  Laura Bover ,  Naoya Tsurushita ,  J. Yun Tso ,  Shankar Kumar

    发明人： Yong-Jun Liu ,  Kui Shin Voo ,  Laura Bover ,  Naoya Tsurushita ,  J. Yun Tso ,  Shankar Kumar

    IPC分类号： C07K16/28

    CPC分类号： C07K16/2878 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/74 ,  C07K2317/75

    摘要： Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided.

    摘要翻译： 公开了与人OX40特异性结合的人抗体，优选重组人抗体，人源化和嵌合。 优选的抗体对OX40受体具有高亲和力，并在体外和体内激活受体。 抗体可以是全长抗体或其抗原结合部分。 抗体或抗体部分可用于调节受体活性，例如在患有OX40活性有害的病症的人类受试者中。 提供用于表达重组人抗体的核酸，载体和宿主细胞，并提供合成重组人抗体的方法。

    Anti-OX40 antibodies and methods of using the same
    3.
    发明授权
    Anti-OX40 antibodies and methods of using the same 有权
    抗OX40抗体及其使用方法

    公开(公告)号：US09006399B2

    公开(公告)日：2015-04-14

    申请号：US13818645

    申请日：2011-08-23

    申请人： Yong-Jun Liu ,  Kui Shin Voo ,  Laura Bover ,  Naoya Tsurushita ,  J. Yun Tso ,  Shankar Kumar

    发明人： Yong-Jun Liu ,  Kui Shin Voo ,  Laura Bover ,  Naoya Tsurushita ,  J. Yun Tso ,  Shankar Kumar

    IPC分类号： C07K16/28 ,  A61K39/395 ,  A61K39/00

    CPC分类号： C07K16/2878 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/74 ,  C07K2317/75

    摘要： Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided.

    摘要翻译： 公开了与人OX40特异性结合的人抗体，优选重组人抗体，人源化和嵌合。 优选的抗体对OX40受体具有高亲和力，并在体外和体内激活受体。 抗体可以是全长抗体或其抗原结合部分。 抗体或抗体部分可用于调节受体活性，例如在患有OX40活性有害的病症的人类受试者中。 提供用于表达重组人抗体的核酸，载体和宿主细胞，并提供合成重组人抗体的方法。

    METHODS OF MODULATING THE OX40 RECEPTOR TO TREAT CANCER
    10.
    发明申请
    METHODS OF MODULATING THE OX40 RECEPTOR TO TREAT CANCER 审中-公开
    调节OX40受体治疗癌症的方法

    公开(公告)号：US20120269825A1

    公开(公告)日：2012-10-25

    申请号：US13456589

    申请日：2012-04-26

    申请人： Yong-Jun Liu ,  Tomoki Ito

    发明人： Yong-Jun Liu ,  Tomoki Ito

    IPC分类号： A61K39/395 ,  G01N33/53 ,  A61P35/00

    CPC分类号： G01N33/5011 ,  A61K2039/505 ,  C07K16/2878 ,  C07K2317/73 ,  C07K2317/75 ,  G01N2333/5434 ,  G01N2333/70578

    摘要： Numerous disease states, such as human allergic, autoimmune, and autoimmune diseases, and cancer, may be treated by targeting OX40/OX40L. OX40L inhibits the generation of Tr1 cells from naïve and memory CD4+ T cells. This unique function of OX40L is not shared by two other costimulatory TNF-family members, GITR-ligand and 4-1BB-ligand. It has been shown that signaling the OX40-receptor on human T cells by antibodies, small molecules, or the OX40L modulates the generation and function of IL-10 producing Foxp3+ Treg immunosuppressive T cells and blocks Foxp3+ Treg function. Further, provided are high throughput methods for identifying compounds that can inhibit the immunosuppressive function of IL-10 producing Tr1 cells.

    摘要翻译： 可以通过靶向OX40 / OX40L来治疗许多疾病状态，例如人类过敏，自身免疫和自身免疫性疾病和癌症。 OX40L抑制从初始和记忆的CD4 + T细胞产生Tr1细胞。 OX40L的这种独特功能不是由另外两种共刺激的TNF-家族成员，GITR-配体和4-1BB-配体共享。 已经表明，通过抗体，小分子或OX40L来传递人T细胞上的OX40受体，调节IL-10产生的Foxp3 + Treg免疫抑制性T细胞的产生和功能并阻断Foxp3 + Treg功能。 此外，提供了用于鉴定可以抑制产生IL-10的Tr1细胞的免疫抑制功能的化合物的高通量方法。